BioArctic AB (publ) (Nasdaq Stockholm: BIOA B), a Swedish research-based biopharma company, announced yesterday that it has started the first clinical study with ABBV-0805 in the United States.

US-based biopharmaceutical company, AbbVie, is responsible for the clinical development of ABBV-0805. The Phase one study in healthy volunteers will investigate the safety and tolerability of the product. It is claimed to be the most advanced within the portfolio of alpha-synuclein targeting antibodies in-licensed by AbbVie from BioArctic in December 2018. The antibody is being evaluated as a disease modifying treatment for Parkinson's disease. It is a result of a strategic research alliance between BioArctic and AbbVie focused on the development of a potential immunotherapy for Parkinson's disease.

Gunilla Osswald, PhD, CEO, BioArctic, said, 'It is gratifying that our partner AbbVie has started the first clinical trial, a Phase 1 study, with ABBV-0805. We are now looking forward to ABBV-0805 moving forward in the clinical program and developing into a therapy with the potential to provide meaningful advances for patients with Parkinson's disease.'